The US Food and Drug Administration approved Takeda's oveporexton, sold under the brand ORZEYFUL, on August 5, 2026 for adults with narcolepsy type 1 (NT1), a chronic neurological disorder marked by orexin deficiency. Takeda says it is the first and only approved drug in the United States that treats the disease itself rather than managing individual symptoms one at a time.
NT1 causes excessive daytime sleepiness, cataplexy (sudden loss of muscle tone triggered by emotion), cognitive symptoms, and fragmented night sleep. Takeda estimates about 120,000 people in the US have the condition, and severity varies from patient to patient.
Oveporexton is an oral drug that selectively activates the orexin 2 receptor, aiming to restore the reduced orexin signaling behind NT1 rather than simply sedating symptoms or suppressing cataplexy episodes. The approval rests on two global Phase 3 trials, FirstLight and RadiantLight, which Takeda says showed statistically significant improvements across daytime sleepiness, cataplexy, and health-related quality of life compared with placebo. The most common side effects reported were insomnia, urinary urgency, increased urination, and excess salivation.
What still has to happen before patients can get it
Approval is not the same as availability. Oveporexton's classification is still under review by the Drug Enforcement Administration, with a decision expected within 90 days. Only after that scheduling determination will Takeda distribute the drug to US clinicians and adult NT1 patients through specialty pharmacies. That sequencing, not the FDA clearance itself, is now the operative timeline for US commercialization.
Takeda's statement is notably restrained on the financial angle: the company says the approval is not expected to materially affect its consolidated earnings forecast for the year ending March 2027. That is a signal about near-term ramp expectations rather than a dismissal of the drug's importance to Takeda's orexin pipeline, which already includes oveporexton (also approved in China), the next-generation candidate TAK-360 aimed at NT1, narcolepsy type 2, and idiopathic hypersomnia, and an additional candidate, TAK-495.
CEO Julie Kim called the approval "a new step" for the NT1 patient community and said Takeda is committed to delivering the therapy "as quickly as possible." Julie Flygare, president of the patient advocacy group Project Sleep and herself an NT1 patient, described the approval as expanding treatment options and offering hope to the community. Emmanuel Mignot, a lead US investigator on the Phase 3 program, said the approval gives doctors and patients a new basis for treatment conversations, after patients had managed NT1 through symptom-relief treatments alone.
The unresolved variable is timing: with the DEA review still open, Takeda has a green light from regulators on efficacy and safety but no fixed date for when US pharmacies can actually fill a prescription.